(19)
(11) EP 1 981 343 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.06.2015 Bulletin 2015/26

(45) Mention of the grant of the patent:
13.05.2015 Bulletin 2015/20

(21) Application number: 07716706.2

(22) Date of filing: 17.01.2007
(51) International Patent Classification (IPC): 
A01N 43/78(2006.01)
 A61K 31/425(2006.01)
(86) International application number:
PCT/US2007/001202
(87) International publication number:
WO 2007/084542 (26.07.2007 Gazette 2007/30)

(54)

TREATMENT OF INFLAMMATORY DISORDERS WITH TRIAZOLE COMPOUNDS

BEHANDLUNG VON ENTZÜNDUNGSERKRANKUNGEN MIT TRIAZOLVERBINDUNGEN

TRAITEMENT DE TROUBLES INFLAMMATOIRES AVEC DES COMPOSES DE TRIAZOLE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 17.01.2006 US 759027 P

(43) Date of publication of application:
22.10.2008 Bulletin 2008/43

(73) Proprietor: Stiefel Laboratories, Inc.
Wilmington, DE 19808 (US)

(72) Inventors:
  • COOLS, Marina
    B-2470 Retie (BE)
  • BORGERS, Marcel
    B-2440 Geel (BE)

(74) Representative: Reeves, Julie Frances 
GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
WO-A1-96/30350
WO-A1-2005/044287
US-A- 6 124 330
 WO-A1-2005/019216
WO-A2-2006/031929
US-B1- 6 787 556
   
  • N. E. MEALY, M. BAYES: "Annual update 2004/2005 - Treatment of dermatological disorders" DRUGS OF THE FUTURE, vol. 30, no. 8, 2005, pages 815-869, XP002605929
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).